KV.A KV Pharmaceutical Co. CL A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act Of 1934

Date of Report (date of earliest event reported): August 3, 2010

 

 

K-V PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

Commission File Number 1-9601

 

Delaware		1-9601		43-0618919
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

One Corporate Woods Drive Bridgeton, MO		63044
(Address of principal executive offices)		(Zip Code)

(314) 645-6600

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act.

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

 

 

---

Item 4.01

Changes in Registrant’s Certifying Accountant.

On August 3, 2010, the Registrant announced in a press release that the Audit Committee of its Board of Directors has engaged BDO USA, LLP (“BDO”) as the Registrant’s independent registered accountant to audit the Registrant’s consolidated financial statements, succeeding KPMG, LLP (“KPMG”).

During the Registrant’s two most recent fiscal years, and the subsequent period prior to engaging BDO, neither the Registrant nor, to the best of the Registrant’s knowledge, anyone acting on the Registrant’s behalf, consulted BDO regarding:

(i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Registrant’s financial statements, and either a written report was provided to the Registrant or oral advice was provided that BDO concluded was an important factor considered by the Registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or

(ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended, and the related instructions to that Item) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

A copy of the press release is attached hereto as Exhibit 99.1. The Registrant will post this Form 8-K on its Internet website at www.kvpharmaceutical.com. References to the Registrant’s website address are included in this Form 8-K and the press release only as inactive textual references and the Registrant does not intend them to be active links to its website. Information contained on the Registrant’s website does not constitute part of this Form 8-K or the press release.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)

The following exhibit is furnished as part of this report:

 

Exhibit Number		Description
99.1		Press Release dated August 3, 2010, issued by K-V Pharmaceutical Company.

*        *        *

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 9, 2010

K-V PHARMACEUTICAL COMPANY

By: /s/ Gregory J. Divis, Jr.

    Gregory J. Divis, Jr.

    Interim President and Interim Chief Executive Officer